DK1235776T3 - Triphenylalkene derivatives and their use as selective estrogen receptor modulators - Google Patents
Triphenylalkene derivatives and their use as selective estrogen receptor modulatorsInfo
- Publication number
- DK1235776T3 DK1235776T3 DK00972945T DK00972945T DK1235776T3 DK 1235776 T3 DK1235776 T3 DK 1235776T3 DK 00972945 T DK00972945 T DK 00972945T DK 00972945 T DK00972945 T DK 00972945T DK 1235776 T3 DK1235776 T3 DK 1235776T3
- Authority
- DK
- Denmark
- Prior art keywords
- estrogen receptor
- selective estrogen
- receptor modulators
- ch2ch2oh
- och3
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
- C07C211/02—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C211/09—Diamines
- C07C211/10—Diaminoethanes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
- C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
- C07C215/16—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic the nitrogen atom of the amino group being further bound to carbon atoms of six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
- C07C217/14—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring
- C07C217/18—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted
- C07C217/20—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted by halogen atoms, by trihalomethyl, nitro or nitroso groups, or by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/10—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C323/11—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/12—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C43/00—Ethers; Compounds having groups, groups or groups
- C07C43/02—Ethers
- C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
- C07C43/225—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C43/00—Ethers; Compounds having groups, groups or groups
- C07C43/02—Ethers
- C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
- C07C43/23—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing hydroxy or O-metal groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
- C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
- C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
- C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Reproductive Health (AREA)
- Pain & Pain Management (AREA)
- Gynecology & Obstetrics (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Urology & Nephrology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Steroid Compounds (AREA)
Abstract
The invention provides novel selective estrogen receptor modulator compounds of the general formula:wherein R1 and R2, which are the same or different area) H, halogen, OCH3, OH; orwhere X is O, NH or S; and n is an integer from 1 to 4; and R4 and R5, which are the same or different, are a 1 to 4 carbon alkyl, H, -CH2C=CH or -CH2CH2OH; or R4 and R5 form an N-containing five- or six-membered ring or heteroaromatic ring; orc) -Y-(CH2)nCH2-O-R6where Y is O, NH or S and n is an integer from 1 to 4; and R6 is H, -CH2CH2OH, or -CH2CH2Cl; ord) 2,3-dihydroxypropoxy, 2-methylsulfamylethoxy, 2-chloroethoxy, 1-ethyl-2-hydroxyethoxy, 2,2-diethyl-2-hydroxyethoxy or carboxymethoxy; andR3 is H, halogen, OH or -OCH3;stereoisomers thereof and their non-toxic pharmaceutically acceptable salts and esters and mixtures thereof, which compounds exhibit valuable pharmacological properties.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16582899P | 1999-11-16 | 1999-11-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1235776T3 true DK1235776T3 (en) | 2006-04-10 |
Family
ID=22600649
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK00972945T DK1235776T3 (en) | 1999-11-16 | 2000-11-01 | Triphenylalkene derivatives and their use as selective estrogen receptor modulators |
Country Status (30)
Country | Link |
---|---|
US (2) | US6576645B1 (en) |
EP (1) | EP1235776B1 (en) |
JP (1) | JP4202647B2 (en) |
KR (2) | KR20080015924A (en) |
CN (2) | CN1263720C (en) |
AT (1) | ATE317378T1 (en) |
AU (1) | AU778296B2 (en) |
BG (1) | BG65853B1 (en) |
BR (1) | BRPI0014901B8 (en) |
CA (1) | CA2390116C (en) |
CZ (1) | CZ304738B6 (en) |
DE (1) | DE60025938T2 (en) |
DK (1) | DK1235776T3 (en) |
EE (1) | EE05126B1 (en) |
ES (1) | ES2253268T3 (en) |
HK (1) | HK1051850A1 (en) |
HR (1) | HRP20020223C1 (en) |
HU (1) | HU228512B1 (en) |
IL (2) | IL148198A0 (en) |
MX (1) | MXPA02002154A (en) |
NO (2) | NO328010B1 (en) |
NZ (1) | NZ518542A (en) |
PL (1) | PL201512B1 (en) |
PT (1) | PT1235776E (en) |
RU (1) | RU2247715C2 (en) |
SK (1) | SK287752B6 (en) |
TW (1) | TW593256B (en) |
UA (1) | UA76409C2 (en) |
WO (1) | WO2001036360A1 (en) |
ZA (1) | ZA200201433B (en) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW593256B (en) * | 1999-11-16 | 2004-06-21 | Hormos Medical Oy Ltd | Triphenylalkene derivatives and their use as selective estrogen receptor modulators |
FI111710B (en) | 2001-05-04 | 2003-09-15 | Hormos Medical Oy Ltd | Process for the preparation of a therapeutically active substance |
US20040248989A1 (en) | 2003-06-05 | 2004-12-09 | Risto Santti | Method for the treatment or prevention of lower urinary tract symptoms |
WO2005012220A2 (en) | 2003-07-28 | 2005-02-10 | Smithkline Beecham Corporation | Cycloalkylidene compounds as modulators of estrogen receptor |
US7196119B2 (en) * | 2003-10-21 | 2007-03-27 | The Regents Of The University Of California | Development of new selective estrogen receptor modulators |
KR20070059110A (en) * | 2004-09-03 | 2007-06-11 | 호르모스 메디칼 리미티드 | Use of a selective estrogen receptor modulator for the manufacture of a pharmaceutical preparation for use in a method for the treatment or prevention of androgen deficiency |
RU2008122993A (en) * | 2005-11-09 | 2009-12-20 | Хормос Медикал Лтд. (Fi) | PREPARATION FORMS OF PHISPEMIFEN |
JP2009516746A (en) * | 2005-11-22 | 2009-04-23 | スミスクライン ビーチャム コーポレーション | Compound |
US20080255078A1 (en) * | 2005-11-22 | 2008-10-16 | Subba Reddy Katamreddy | Triphenylethylene Compounds Useful as Selective Estrogen Receptor Modulators |
CN101360488A (en) * | 2005-11-22 | 2009-02-04 | 史密丝克莱恩比彻姆公司 | Chemical compounds |
US20080234199A1 (en) * | 2005-11-22 | 2008-09-25 | Smithkline Beecham Corporation | Chemical Compounds |
MX2008014825A (en) | 2006-05-22 | 2008-12-01 | Hormos Medical Ltd | Selective estrogen receptor modulators or aromatase inhibitors for treating chronic nonbacterial prostatitis. |
PL2121553T3 (en) * | 2007-02-14 | 2012-11-30 | Hormos Medical Ltd | Method for the preparation of therapeutically valuable triphenylbutene derivatives |
US7504530B2 (en) | 2007-02-14 | 2009-03-17 | Hormos Medical Ltd. | Methods for the preparation of fispemifene from ospemifene |
WO2008157335A2 (en) | 2007-06-13 | 2008-12-24 | Quatrx Pharmaceuticals Company | Methods for the treatment of erectile dysfunction using fispemifene |
CA2702710C (en) | 2007-10-16 | 2013-05-07 | Repros Therapeutics, Inc. | Trans-clomiphene for metabolic syndrome |
WO2009120999A2 (en) * | 2008-03-28 | 2009-10-01 | Olema Pharmaceuticals, Inc. | Use of an endoxifen prodrug for treatment of breast cancer |
US8318667B2 (en) | 2009-02-25 | 2012-11-27 | Merck Sharp & Dohme Corp. | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use |
PL2526080T3 (en) * | 2010-01-19 | 2014-08-29 | Cambrex Karlskoga Ab | New processes for producing benzophenone derivatives |
RU2584156C2 (en) * | 2010-05-20 | 2016-05-20 | Басф Се | Derivatives of tris(2-hydroxyphenyl)methane, their preparation and use |
DE102010027016A1 (en) | 2010-07-09 | 2012-01-12 | Universitätsklinikum Jena | New steroid-styryl dye conjugates useful e.g. for simulation and direct light optical detection of the behavior of steroid in the living biological tissue in the presence of a steroid binding protein |
GB2483736B (en) | 2010-09-16 | 2012-08-29 | Aragon Pharmaceuticals Inc | Estrogen receptor modulators and uses thereof |
KR101308258B1 (en) * | 2010-10-15 | 2013-09-13 | 씨제이제일제당 (주) | A novel method of making Endoxifen |
CN102584687A (en) * | 2011-12-30 | 2012-07-18 | 北京赛林泰医药技术有限公司 | Ethylene derivatives used as selective estrogen receptor modulators |
CN102532073A (en) * | 2011-12-30 | 2012-07-04 | 北京赛林泰医药技术有限公司 | Ethylene derivative serving as selective estrogen receptor modulators (SERMs) |
AU2012361344A1 (en) * | 2011-12-30 | 2014-07-24 | Centaurus Biopharma Co., Ltd. | Novel arylalkene derivatives and use thereof as selective estrogen receptor modulators |
CA2865234A1 (en) | 2012-02-29 | 2013-09-06 | Repros Therapeutics Inc. | Combination therapy for treating androgen deficiency |
CN104220426B (en) | 2012-03-20 | 2017-03-01 | 塞拉根制药公司 | Estrogenic agents and application thereof |
JP2015532309A (en) | 2012-10-19 | 2015-11-09 | フェルミオン オサケ ユキチュア | Ospemifen production method |
WO2014060639A1 (en) | 2012-10-19 | 2014-04-24 | Fermion Oy | A process for the preparation of ospemifene |
IN2013MU00646A (en) * | 2013-03-04 | 2015-06-26 | Intas Pharmaceuticals Ltd | |
US9744177B2 (en) | 2014-03-10 | 2017-08-29 | Endorecherche, Inc. | Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with SERM |
JPWO2016043189A1 (en) * | 2014-09-16 | 2017-06-29 | 塩野義製薬株式会社 | Method for producing triphenylbutene derivative |
CA2971216A1 (en) | 2014-12-23 | 2016-06-30 | The Regents Of The University Of California | Methods for immunomodulation of cancer and infectious disease therapy |
AU2016352592B2 (en) | 2015-11-10 | 2023-04-27 | Paracrine Therapeutics Ab | Treatment of ER-negative breast cancer with an PDGF-CC inhibitor and an anti estrogen |
AU2017232476B2 (en) | 2016-03-15 | 2019-10-03 | Shionogi & Co., Ltd. | Method for producing phenoxyethanol derivative |
KR101819639B1 (en) * | 2016-06-27 | 2018-01-17 | 주식회사 케미메디 | Novel aryl ethene derivatives and pharmaceutical composition containing the same as an active ingredient |
WO2018004066A1 (en) * | 2016-06-27 | 2018-01-04 | 주식회사한국전통의학연구소 | Novel aryl ethane derivative and pharmaceutical composition containing same as active ingredient |
KR102052133B1 (en) * | 2017-08-10 | 2019-12-05 | 고려대학교 산학협력단 | Glycosyl-attached Ospemifene, Method for Preparing Thereof and Pharmaceutical Compositions Containing The Same as Active Ingredients |
US11325883B2 (en) | 2017-11-22 | 2022-05-10 | Temple University—Of the Commonwealth System of Higher Education | Functionalized N,N-dialkylamino phenyl ethers and their method of use |
CA3120530A1 (en) * | 2018-11-21 | 2020-05-28 | Accutar Biotechnology Inc. | Novel compounds having estrogen receptor alpha degradation activity and uses thereof |
CA3161892A1 (en) | 2019-12-23 | 2021-07-01 | Jie Fan | Combinations of estrogen receptor degraders and cyclin-dependent kinase inhibitors for treating cancer |
US11413270B2 (en) | 2020-06-22 | 2022-08-16 | Novmetapharma Co., Ltd. | Method for the treatment of pancreatitis |
WO2022029657A1 (en) | 2020-08-04 | 2022-02-10 | Novmetahealth Co., Ltd. | Method for treatment of cytokine release syndrome |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE637389A (en) | 1962-09-13 | |||
GB2042519B (en) * | 1979-01-17 | 1983-03-23 | Biorex Laboratories Ltd | 1,1,2-triphenylethane and -ehylene derivatives |
US4656187A (en) | 1981-08-03 | 1987-04-07 | Eli Lilly And Company | Treatment of mammary cancer |
FI77839C (en) * | 1982-05-27 | 1989-05-10 | Farmos Oy | FOERFARANDE FOER FRAMSTAELLNING AV NYA THERAPEUTIC EFFECTIVE TRIPHENYLALKAN- OCH ALKENDERIVAT. |
GB2126576B (en) * | 1982-06-25 | 1985-06-19 | Farmos Group Limited | Alkane and alkene derivatives |
FI67538C (en) * | 1982-05-27 | 1985-04-10 | Farmos Oy | PROCEDURE FOR FRAMSTATION OF AV (Z) -1,2-DIPHENYL-1- (4- (2- (N N-DIMETHYLAMINO) ETHOXY) PHENYL) -1-BUTEN |
US5491173A (en) | 1982-06-25 | 1996-02-13 | Orion-Yhtyma Oy | Tri-phenyl alkene derivatives and their preparation and use |
US4729999A (en) | 1984-10-12 | 1988-03-08 | Bcm Technologies | Antiestrogen therapy for symptoms of estrogen deficiency |
EP0260066B1 (en) * | 1986-09-11 | 1990-05-09 | National Research Development Corporation | Tamoxifen derivatives |
US5189212A (en) | 1990-09-07 | 1993-02-23 | University Of Georgia Research Foundation, Inc. | Triarylethylene carboxylic acids with estrogenic activity |
US5219548A (en) | 1990-10-01 | 1993-06-15 | Board Of Regents, The University Of Texas System | High affinity halogenated-tamoxifen derivatives and uses thereof |
US6096874A (en) | 1990-10-01 | 2000-08-01 | Board Of Regents, The University Of Texas System | High affinity tamoxifen derivatives |
CA2092996A1 (en) | 1990-10-01 | 1992-04-02 | David Yang | High affinity tamoxifen derivatives and uses thereof |
US5118667A (en) | 1991-05-03 | 1992-06-02 | Celtrix Pharmaceuticals, Inc. | Bone growth factors and inhibitors of bone resorption for promoting bone formation |
US5196435A (en) | 1991-11-21 | 1993-03-23 | Eli Lilly And Company | Melatonin derivatives and combinations with antiestrogen compounds for treating mammalian breast carcinoma |
GB9207437D0 (en) | 1992-04-03 | 1992-05-20 | Orion Yhtymae Oy | Topical administration of toremifene and its metabolites |
US5446203A (en) | 1992-08-25 | 1995-08-29 | New York University | Synthesis of haloenones and aryl or alkyl substituted enones or alkenes |
DE4335876A1 (en) | 1993-10-17 | 1995-04-20 | Schering Ag | Combination of progesterone antagonists and partial agonist antiestrogens for hormone replacement therapy for peri- and postmenopausal women |
US5650425A (en) | 1994-04-04 | 1997-07-22 | Pharmos Corporation | Permanently ionic derivatives of steroid hormones and their antagonists |
US5681835A (en) | 1994-04-25 | 1997-10-28 | Glaxo Wellcome Inc. | Non-steroidal ligands for the estrogen receptor |
US5604248A (en) | 1994-05-05 | 1997-02-18 | Eli Lilly And Company | Method for minimizing the uterotrophic effect of tamoxifen and tamoxifen analogs |
US5470883A (en) | 1994-05-23 | 1995-11-28 | Stromberg; Brent V. | Method of treating peripheral vasoconstriction with tamoxifen citrate |
US5441986A (en) | 1994-07-19 | 1995-08-15 | Pfizer Inc. | Estrogen agonists as remedies for prostate and cardiovascular diseases |
GB9418067D0 (en) * | 1994-09-07 | 1994-10-26 | Orion Yhtymae Oy | Triphenylethylenes for the prevention and treatment of osteoporosis |
US5658931A (en) | 1994-09-20 | 1997-08-19 | Eli Lilly And Company | Method for inhibiting mammalian breast carcinoma with tamoxifen, and analogs thereof, and certain naphthyl compounds |
MX9703944A (en) | 1994-11-29 | 1998-05-31 | Hoechst Marion Roussel Inc | Method of using triaryl-ethylene derivatives in the treatment and prevention of osteoporosis. |
US5821254A (en) | 1995-02-17 | 1998-10-13 | The United States Of America As Represented By The Department Of Health And Human Services | Uses of 9-cis-retinoic acids and derivatives thereof alone or in combination with antineoplastic agents in the prevention or treatment of cancer |
GB9509572D0 (en) * | 1995-05-11 | 1995-07-05 | Cancer Res Campaign Tech | Cancer therapy |
DE19526146A1 (en) | 1995-07-07 | 1997-01-09 | Schering Ag | Triphenylethylenes, processes for their preparation, pharmaceutical preparations containing these triphenylethylenes and their use for the preparation of medicaments |
GB9604577D0 (en) * | 1996-03-04 | 1996-05-01 | Orion Yhtymae Oy | Serum cholesterol lowering agent |
GB9803521D0 (en) * | 1998-02-19 | 1998-04-15 | Orion Yhtymo Oy | New compounds and pharmaceutical compositions thereof |
US6465445B1 (en) * | 1998-06-11 | 2002-10-15 | Endorecherche, Inc. | Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors |
TW593256B (en) * | 1999-11-16 | 2004-06-21 | Hormos Medical Oy Ltd | Triphenylalkene derivatives and their use as selective estrogen receptor modulators |
-
2000
- 2000-10-20 TW TW089122073A patent/TW593256B/en not_active IP Right Cessation
- 2000-11-01 DK DK00972945T patent/DK1235776T3/en active
- 2000-11-01 CZ CZ2002-1623A patent/CZ304738B6/en not_active IP Right Cessation
- 2000-11-01 RU RU2002115871/04A patent/RU2247715C2/en active
- 2000-11-01 CA CA002390116A patent/CA2390116C/en not_active Expired - Lifetime
- 2000-11-01 IL IL14819800A patent/IL148198A0/en unknown
- 2000-11-01 UA UA2002065002A patent/UA76409C2/en unknown
- 2000-11-01 MX MXPA02002154A patent/MXPA02002154A/en active IP Right Grant
- 2000-11-01 PL PL355708A patent/PL201512B1/en unknown
- 2000-11-01 BR BRPI0014901A patent/BRPI0014901B8/en not_active IP Right Cessation
- 2000-11-01 EP EP00972945A patent/EP1235776B1/en not_active Expired - Lifetime
- 2000-11-01 AU AU11503/01A patent/AU778296B2/en not_active Ceased
- 2000-11-01 DE DE60025938T patent/DE60025938T2/en not_active Expired - Lifetime
- 2000-11-01 CN CNB008156255A patent/CN1263720C/en not_active Expired - Lifetime
- 2000-11-01 JP JP2001538315A patent/JP4202647B2/en not_active Expired - Lifetime
- 2000-11-01 KR KR1020087000375A patent/KR20080015924A/en not_active Application Discontinuation
- 2000-11-01 PT PT00972945T patent/PT1235776E/en unknown
- 2000-11-01 ES ES00972945T patent/ES2253268T3/en not_active Expired - Lifetime
- 2000-11-01 WO PCT/FI2000/000946 patent/WO2001036360A1/en active IP Right Grant
- 2000-11-01 AT AT00972945T patent/ATE317378T1/en active
- 2000-11-01 KR KR1020027006302A patent/KR100877487B1/en active IP Right Grant
- 2000-11-01 HU HU0204029A patent/HU228512B1/en not_active IP Right Cessation
- 2000-11-01 CN CNB200610084709XA patent/CN100441556C/en not_active Expired - Lifetime
- 2000-11-01 EE EEP200200190A patent/EE05126B1/en unknown
- 2000-11-01 SK SK671-2002A patent/SK287752B6/en not_active IP Right Cessation
- 2000-11-01 NZ NZ518542A patent/NZ518542A/en not_active IP Right Cessation
- 2000-11-15 US US09/712,252 patent/US6576645B1/en not_active Expired - Lifetime
-
2002
- 2002-02-14 BG BG106413A patent/BG65853B1/en unknown
- 2002-02-17 IL IL148198A patent/IL148198A/en not_active IP Right Cessation
- 2002-02-20 ZA ZA200201433A patent/ZA200201433B/en unknown
- 2002-03-14 HR HR20020223 patent/HRP20020223C1/en not_active IP Right Cessation
- 2002-05-15 NO NO20022317A patent/NO328010B1/en not_active IP Right Cessation
-
2003
- 2003-04-08 US US10/408,303 patent/US6875775B2/en not_active Expired - Lifetime
- 2003-06-10 HK HK03104083A patent/HK1051850A1/en not_active IP Right Cessation
-
2009
- 2009-10-20 NO NO20093175A patent/NO332328B1/en not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1235776T3 (en) | Triphenylalkene derivatives and their use as selective estrogen receptor modulators | |
MY114679A (en) | Aroyl-piperidine derivatives | |
DK1260512T3 (en) | Hitherto unknown cyclic amide derivatives | |
ES2185338T3 (en) | DERIVATIVES OF FUMAGILOL AND PROCEDURES FOR ITS MANUFACTURE. | |
HRP20000854B1 (en) | Therapeutic biaryl derivatives | |
HRP20030003B1 (en) | N-oxides as nk1 receptor antagonist prodrugs of 4-phenyl-pyridine derivatives | |
TR200100698T2 (en) | Dihydrobenzodioxin Carboxamide and Ketone derivatives as 5-HT4 receptor-Antagonists | |
DE69530094D1 (en) | THIAZOLIDINDIONE DERIVATIVES, THEIR PRODUCTION AND USE | |
DK0484223T3 (en) | 3-cyclopropanamides, their tautomeric forms and their salts, and a process for their preparation, their use as drugs and preparations containing them | |
ES2191341T3 (en) | DERIVATIVES OF 2-PHENOXIANILINE. | |
HUP0303361A2 (en) | Substituted 1-aminobutan-3-ol derivatives, process for their preparation and pharmaceutical compositions containing them | |
RS50289B (en) | Novel branched substituted amino derivatives of 3-amino-1- phenyl-1h(1,2,4)triazol,methods for producing them and pharmaceutical compositions containing them | |
AR034313A1 (en) | USE OF PIRIDOINDOLONE DERIVATIVES FOR THE PREPARATION OF MEDICINES | |
NO20040113L (en) | Variolin derivatives and their use as antitumor agents | |
EP0785191A4 (en) | Fused indan derivatives and salts thereof | |
DE69828087D1 (en) | AMIN DERIVATIVES | |
NO955071L (en) | monkey Ergoline derivatives as 5HT1A ligands | |
CO4940434A1 (en) | THERAPEUTIC DERIVATIVES OF NAFTALENE | |
WO2001064671A3 (en) | Haloimidazole derivatives and their use as muscarinic m3 and serotoninergic 5-ht4 receptors | |
SE9002445L (en) | NEW CYCLOBUTAN DERIVATIVE AND PROCEDURE FOR PREPARING THE SAME | |
ES464875A1 (en) | Tetracyclic compounds | |
TH34907A (en) | New compound |